Jounce Therapeutics to Present Data from its JTX-2011 and JTX-8064 Programs at the 2019 American Association for Cancer Resea...
February 27 2019 - 4:35PM
ICONIC Clinical Data Demonstrates Improved PFS/OS
in Patients with Emergence of JTX-2011 Mechanistic Biomarker (ICOS
high CD4 T cells)
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that
data from its Phase 1/2 ICONIC trial, an open label trial
evaluating JTX-2011 monotherapy and in combination with nivolumab,
will be the subject of two poster presentations at the upcoming
2019 American Association for Cancer Research (AACR) Annual Meeting
at the Georgia World Congress Center in Atlanta, GA on March 31-
April 3, 2019. In addition, Jounce Therapeutics will present a
poster that will describe the preclinical evaluation of JTX-8064, a
highly specific monoclonal antibody that aims to reprogram human
macrophages from an immune suppressive to immune active state by
inhibiting the cell surface receptor LILRB2.
“The JTX-2011 clinical data being presented show that ICONIC
patients with emergence of ICOS hi CD4 T cells in the peripheral
blood have improved progression free and overall survival. This
finding further validates the role of this ICOS pharmacodynamic
biomarker in directing the next stage of the clinical development
strategy for JTX-2011. Establishing the importance of this
biomarker and its association with improved survival leads us to
two distinct paths; first, combination with other agents that are
known to induce ICOS hi CD4 T cells which JTX-2011 may then further
stimulate; and second, using candidate predictive biomarkers
identified through analysis of baseline samples of patients with
and without emergence of these cells,” said Elizabeth Trehu, M.D.,
chief medical officer of Jounce Therapeutics. “In addition to the
data from our JTX-2011 program, we will also highlight JTX-8064 and
the preclinical evaluation of this novel product candidate and its
role in reprogramming tumor-associated macrophages within the tumor
microenvironment.”
JTX-2011 Posters Details:Improved
progression-free and overall survival (PFS/OS) in patients (pts)
with emergence of JTX-2011 associated biomarker (ICOS high CD4 T
cells) on the ICONIC trialSession Title: Phase II-III
Clinical Trials: Part 2 Location: Exhibit Hall B, Poster Section
16Date and Time: Tuesday April 2, 2019 1:00 PM - 5:00 PM ETPoster
Board Number: 3; Permanent Abstract Number: CT189
Genetic and molecular profiling of ICOS hi CD4 T cells
demonstrates clonal expansion of TH1 effector cells following
JTX-2011 treatment in subjects with solid tumorsSession
Title: Biomarkers and Immune Monitoring Location: Exhibit Hall B,
Poster Section 22Date and Time: Tuesday April 2, 2019 1:00 PM -
5:00 PM ETPoster Board Number: 16; Permanent Abstract Number:
4053
JTX-8064 Poster Details:Preclinical
evaluation of JTX-8064, an anti-LILRB2 antagonist antibody, for
reprogramming tumor-associated macrophagesSession Title:
Tumor Immune MicroenvironmentLocation: Exhibit Hall B, Poster
Section 25Date and Time: Wednesday April 3, 2019 8:00 AM - 12:00 PM
ETPoster Board Number: 1; Permanent Abstract Number: 5007
The posters will be available at the start of each session on
the “Our Approach” section of the Jounce Therapeutics website at
www.jouncetx.com.
Jounce Therapeutics to Host Event and
WebcastJounce Therapeutics will host an investor and
analyst event beginning at 6:30 p.m. ET and live webcast beginning
at 7:00 p.m. ET, on Tuesday, April 2, 2019. To access the live
webcast, please visit the “Events & Presentations” page in the
Investors and Media section of the company’s website at
www.jouncetx.com. The webcast will be archived and made available
for replay on the company’s website approximately two hours after
the call and will be available for 30 days thereafter.
About JTX-2011Jounce’s lead product candidate,
JTX-2011, is a monoclonal antibody that binds to and activates
ICOS, a protein on the surface of certain T cells. The company is
developing JTX-2011 to treat solid tumors as a single agent and in
combination with other therapies.
About JTX-8064JTX-8064 is an anti-Leukocyte
Immunoglobulin Like Receptor B2 (LILRB2) antibody and is the first
candidate to emerge from Jounce’s Translational Science Platform
efforts that focuses on tumor-associated macrophages. JTX-8064 is
currently in IND-enabling activities and Jounce anticipates filing
an IND and initiating a Phase 1 clinical trial for JTX-8064 in
2019.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within the
human tumor microenvironment to prioritize targets, and then
identifies related biomarkers designed to match the right
immunotherapy to the right patient. Jounce has three
development-stage programs: its two clinical product candidates,
JTX-2011, a monoclonal antibody that binds to and activates ICOS,
and JTX-4014, a monoclonal antibody that binds to PD-1 and for
potential use in combination with Jounce’s pipeline of future
product candidates, and JTX-8064, a monoclonal antibody that binds
to LILRB2 that is currently in the IND-enabling phase. For more
information, please visit www.jouncetx.com.
Forward-Looking StatementsStatements in this
release concerning Jounce’s future expectations and plans,
including without limitation, Jounce’s expectations regarding the
timing, progress and results of the clinical development of
JTX-2011 and JTX-8064, and Jounce’s clinical development strategy
may constitute forward looking statements for the purposes of the
safe harbor provisions under The Private Securities Litigation
Reform Act of 1995 and other federal securities laws and are
subject to substantial risks, uncertainties and assumptions. You
should not place reliance on these forward looking statements,
which include words such as “aims,” “anticipates,” “intend,” “may,”
“potential” or similar terms, variations of such terms or the
negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Actual
results may differ materially from those indicated by these
forward-looking statements as a result of various important
factors, as well as those risks more fully discussed in the section
entitled “Risk Factors” in Jounce’s most recent annual report on
Form 10-K or quarterly report on Form 10-Q, as well as discussions
of potential risks, uncertainties, and other important factors in
Jounce’s subsequent filings with the U.S. Securities and Exchange
Commission. All such statements speak only as of the date made, and
the Company undertakes no obligation to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Contact: Komal Joshi Jounce
Therapeutics, Inc. (857) 320-2523 kjoshi@jouncetx.com
Media Contact: Gina Nugent The Yates Network
(617) 460-3579 gina@theyatesnetwork.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024